This is not only because the agreements provided simultaneously for the limitation of generic market
entry and for significant value transfers, but is also due to some further aggravating factors: the payments amounted to the expected profits of the generics had they entered the market; the real purpose was not to resolve the underlying patent dispute between the parties insofar as the agreements did not provide for market
entry upon their expiration; and the content of the agreements went beyond the scope of Lundbeck's patents, since they were intended to prevent the sales of all types of generic citalopram while Lundbeck could not have obtained the same
outcome through the enforcement of its patents.